Astrocytoma, IDH-mutant, grade 4

What it is

An astrocytoma, IDH-mutant, CNS WHO grade 4 is the highest-grade IDH-mutant astrocytoma, showing the most aggressive features (such as necrosis, abnormal blood vessel growth, or the molecular marker CDKN2A/B homozygous deletion). In the 2021 classification, it is no longer called "glioblastoma," a term now reserved for IDH-wildtype tumors.

Understanding Astrocytoma, IDH-mutant, grade 4

A key change in the modern classification is that an IDH-mutant astrocytoma at grade 4 is a distinct diagnosis from glioblastoma (which is IDH-wildtype). Although grade 4 is the most aggressive grade, the favorable IDH mutation means these tumors generally have a better outlook than IDH-wildtype glioblastoma. Grade 4 can be assigned based on aggressive appearance or on the molecular marker CDKN2A/B homozygous deletion. Treatment is intensive — typically surgery, radiation, and chemotherapy — similar in approach to glioblastoma, but the outlook is generally more favorable owing to the IDH mutation. This distinction matters for prognosis and counseling. Understanding the IDH-mutant grade 4 astrocytoma clarifies the most aggressive IDH-mutant astrocytoma and how it differs from glioblastoma.

Why it matters

Understanding the IDH-mutant grade 4 astrocytoma helps patients and families see that, although it is the highest grade, the favorable IDH mutation gives it a generally better outlook than IDH-wildtype glioblastoma — an important distinction.